SLC5A2 and chronic kidney disease: The mainstay of the pharmacological management of CKD in T2DM are RAS inhibition, SGLT-2 inhibition, GLP-1 RA, nsMRA, and lipid-lowering therapy in conjunction with lifestyle modification to reduce the progression of CKD and CVD risk.